1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
Chennai Meenakshi Multispeciality Hospital Limited

Chennai Meenakshi Multispeciality Hospital Limited

CMMHOSP.BO
Chennai Meenakshi Multispeciality Hospital LimitedIN flagBombay Stock Exchange
38.51
INR
-0.89
- -
287.63MMarket Cap
Chennai Meenakshi Multispeciality Hospital Limited
CMMHOSP.BO
(Bombay Stock Exchange)

Recent

price

38.51

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
16.64
19.76
21.32
23.7
25.27
27.49
25.22
31.2
29.73
34.29
25.99
41.92
51.7
50.94
46.64
- -
50.1
Revenue per Share
-1.07
0.09
0.92
0.6
-1.3
0.88
-1.42
2
0.07
0.74
-1.67
5.32
1.19
-0.57
-1.84
- -
-1.56
Basic EPS, GAAP
-1.86
1.4
3.84
2.47
3.28
2
2.75
0.69
1.93
2.56
4.04
2.09
2.49
-0.16
2.55
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-8.44
-8.35
-7.43
-6.83
-8.13
-7.25
-8.48
-6.39
-6.33
-5.57
-7.19
-1.84
-1.02
-1.6
-3.44
- -
10.1
Book Value per Share
-7.64
-7.54
-6.62
-6.03
-7.33
-6.45
-7.68
-5.59
-5.53
-4.77
-6.39
-1.04
0.16
-0.44
-2.53
- -
-4.16
Tangible Book Value per Share
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
- -
7
Basic Weighted Avg Shares
124
148
159
177
189
205
188
233
222
256
194
313
386
380
348
370
370
Sales/Revenue/Turnover
3.62
10.18
12.27
9.12
5.18
9.16
0.46
10.74
3.5
4.38
-3.04
14.35
4.54
1.53
-3.93
-3.65
-3.75
Operating Margin (%)
6
7
7
8
18
12
11
11
12
12
13
12
12
12
12
11
11
Depreciation Expense
-8
1
7
4
-10
7
-11
15
- -
5
-12
40
9
-4
-14
-11
-12
Net Income, GAAP
- -
- -
- -
7.35
- -
- -
- -
- -
- -
- -
- -
- -
30.46
511.75
- -
- -
- -
Effective Tax Rate (%)
-6.45
0.48
4.31
2.52
-5.15
3.19
-5.62
6.43
0.22
2.14
-6.44
12.7
2.31
-1.12
-3.95
-3.02
-3.11
Profit Margin (%)
-49
-50
-63
-78
-88
-72
-75
-69
-66
-57
-59
-37
-25
-38
-57
-40
-40
Working Capital
134
135
127
121
115
115
115
115
115
115
115
106
106
110
106
106
106
LT Debt
-57
-56
-49
-45
-55
-48
-57
-42
-41
-36
-48
-8
1
-3
-19
-31
-31
Total Equity
- -
14.15
22.82
18.1
- -
26.81
- -
34.32
9.61
14.02
- -
54.29
11.84
-21.97
- -
- -
- -
Return on Invested Capital (%)
- -
15.64
26.53
21.32
- -
28.51
- -
39.28
15.89
22.61
- -
61.82
14.74
-35.39
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-12.16
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
106
- -
106
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
- -
7
Market Capitalization
326
344
244

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
87
- -
82
Cash, Cash Equivalents & STI
47
- -
52
Accounts Receivable, Net
8
- -
9
Inventories
5
- -
4
Total Current Liabilities
125
- -
122
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.85%
-5.89%
62.95%
Free Cash Flow
-171.26%
-388.85%
-85.93%
Net Income, GAAP
-33.97%
-88.2%
-18.67%
Sales/Revenue/Turnover
8.29%
16.21%
6.38%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
91
95
101
168
380
2025
87
81
88
92
348
2026
86
95
91
98
370

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.06
-0.05
- -
-0.57
2025
-0.51
-0.9
-0.84
0.42
-1.84
2026
-0.99
0.2
-0.72
-0.03
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Dr. Sulaiman Al Habib Medical Services Group Company (4013.SR)
Medicover AB (publ) (MCVEF)
Elan Corporation (6099.T)
Guangdong Kanghua Healthcare Group Co., Ltd. (3689.HK)
Cross Country Healthcare, Inc. (CCRN)
Mega Genomics Limited (6667.HK)
Business
Chennai Meenakshi Multispeciality Hospital Limited operates a 100-bedded multispeciality hospital in Mylapore, Chennai, India, offering comprehensive healthcare services including cardiology with ECG, echocardiography, and treadmill facilities; plastic surgery; dermatology; diabetology; dentistry; ENT; general medicine and surgery; gynaecology; haematology; nephrology; neurology and neurosurgery; oncology; ophthalmology; orthopaedics; paediatrics and paediatric gastroenterology; psychiatry; pulmonology; radiology; rheumatology; surgical gastroenterology; surgical oncology; urology; vascular surgery; and physiotherapy, alongside diagnostic services such as CT scan, laboratory testing, 24-hour emergency care, dialysis unit, and pharmacy product sales. Founded in 1990 as Devaki Hospital Limited and renamed Chennai Meenakshi Multispeciality Hospital Limited in 2008, the company is headquartered at No. 70, Luz Church Road, Mylapore, Chennai, Tamil Nadu, and lists its shares on the Bombay Stock Exchange under scrip code 523489. The hospital maintains ISO 9001:2008 and ISO 14001:2004 certifications for its management and environmental systems, as obtained in 2014, and provides round-the-clock accident and emergency care as a pioneer in handling medico-legal cases since its origins in 1978 under Eskeycee Medical Foundations Private Limited. Recent board changes include the appointment of Mrs. Jayanthi Radhakrishnan as non-executive director effective September 20, 2023; transition of company secretaries with Mr. Bharatraj Panchal's resignation on July 14, 2025, following his appointment in March 2024; appointment of new statutory auditors M/s. Elias George & Co. in September 2024 for five years; change of independent director appointment letters in 2025 for Ms. Shama Dhilip and Mr. Kanderi Munuswamy Mohandass; and scheduled board meetings such as on November 13, 2025, alongside routine governance actions like trading window closures and financial result announcements for quarters ending June 2025 showing net losses. The company continues operations without reported major acquisitions, funding rounds, or expansions in 2024-2025, focusing on regulatory compliance and investor communications through its website and BSE filings.